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Objectives: Poor survival of high-grade serous pelvic cancer is caused by a lack of ef-
fective screening measures. The detection of exfoliated cells from high-grade serous pelvic
cancer, or precursor lesions, is a promising concept for earlier diagnosis. However,
collecting those cells in the most efficient way while fulfilling all requirements for a
screening approach is a challenge. We introduce a new catheter for uterine and tubal lavage
(UtL) and the clinical evaluation of its performance.
Methods/Materials: In study I, the clinical feasibility of the UtL using the new catheter
was examined in 93 patients admitted for gynecologic surgery under general anesthesia. In
study II, the safety of the UtL procedure was assessed. The pain during and after the UtL
performed under local anesthesia was rated on a visual analog scale by 22 healthy women.
Results: In study I, the UtL was carried out successfully in 92 (98.9%) of 93 cases by 16
different gynecologists. It was rated as easy to perform in 84.8% of patients but as rather
difficult in cancer patients (odds ratio, 5.559; 95% confidence interval, 1.434Y21.546; P =
0.007). For benign conditions, dilatation before UtL was associated with menopause status
(odds ratio, 4.929; 95% confidence interval, 1.439Y16.884; P = 0.016). In study II, the pain
duringUtLwas ratedwith amedianvisual analog scale score of 1.6.During a period of 4weeks
after UtL, none of the participants had to use medication or developed symptoms requiring
medical attention. The UtL took 6.5 minutes on average. The amount of extracted DNAwas
above the lower limit for a sensitive, deep-sequencing mutation analysis in all cases.
Conclusions: Our studies demonstrate that the UtL, using the new catheter, is a safe,
reliable, and well-tolerated procedure, which does not require elaborate training. Therefore,
UtL fulfils all prerequisites to be used in a potential screening setting.
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H igh-grade serous pelvic cancer (HGSC) is usually diag-nosed at advanced stage with a 10-year survival rate of
less than 30%.1 This is caused by a lack of early symptoms
and effective screening measures. All previous attempts to
establish an effective screening strategy failed in both the
general and the high-risk breast and ovarian cancer (HBOC)
population, for example, BRCA germline mutation carriers.2,3
To date, risk-reducing salpingo-oophorectomy (RRSO) is still
considered the only way for HBOC women to reduce their
risk of HGSC development. However, RRSO results in seri-
ous adverse effects. In addition to the loss of reproductive
capacity, these involve different problems associated with
premature menopause.4,5
A new, promising diagnostic concept based on the fact
that the vagina, cervical canal, uterine cavity, fallopian tubes,
ovarian surface, and peritoneal cavity form a communicating
space was introduced by several groups. This concept aims at
detecting exfoliated cells from HGSC and the precursor le-
sion, serous tubal intraepithelial carcinoma (STIC).6 So far,
the collection of these shed cells was achieved through 3
different approaches: by the use of tampons, a liquid-based
Papanicolaou test and a uterine and tubal lavage (UtL). The
level of invasiveness of the approaches increases in the
aforementioned order. However, the results of different
studies suggest that the efficiency of target cell collection
increases in the same manner,7Y9 most probably because UtL
allows cells to be collected closest to their origin.
While establishing a protocol for UtL, we encountered
several problems and none of the existing catheters were able
to overcome those. Problems resulted from the fact that the
uterine cavity is very small and that the anterior and posterior
wall lie on top of each other. Therefore, fluid that was flushed
into the cavity either immediately evacuated through the
tubes, or a backflowof the fluid into the vaginawas noticed. In
either way, the total volume of the UtL could not be recovered.
Furthermore, the tip of comparable catheters frequently got
clogged, and the procedure could not be continued (data not
published). An innovative catheter that overcomes these
technical problems has recently been developed. To demon-
strate the safety of the catheter and the clinical feasibility of
this diagnostic approach, 2 studies were performed.
Study I aimed at assessing the clinical feasibility of the
UtL approach using the new catheter. It was conducted as a
multicenter trial, and 16 clinicians reported on their experi-
ences while performing the UtL. Furthermore, this study
aimed at evaluating whether the amount of DNA isolated from
the UtL specimen would be sufficient for future HGSC and/or
STIC detection by sequencing of TP53.
Study II aimed at investigating the practicality and
safety of the UtL approach as a potential screening test. The
FIGURE 1. Sketch of the catheter for UtL (Medicoplast MF 13005). The 12F flexible polyurethane 3-way catheter
comprises a polyurethane tubewith 3 lumens. There are 2 lavage channels eachwith 2 openings, one on the tip of the
catheter facing forward and one at the side. The third channel is the balloon tube carrying a valve, which is used to
seal the cervical canal.
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UtL was performed under local anesthesia (LA) only and
compared with the placement of an intrauterine device (IUD).
This comparison was chosen because IUD placement follows
the same steps as the UtL; it is a procedure that is well known
to gynecologists and broadly accepted by women.
MATERIALS AND METHODS
Theused catheter forUtL (Fig. 1;MF13005;Medicoplast,
Illingen, Germany; developed in cooperation with the
Katholieke Universiteit Leuven) is a proprietary 12F flexible 3-
way catheter. It comprises a polyurethane tube with 3 lumens,
which are separated into 3 tubes with a 3-way distributor.
Two tubes function as lavage channels and carry a Luer-
Lock female connector at the proximal end. Each of the
lavage channels has 2 openings: one at the tip of the
catheter facing forward and one at the side. The third tube is
the balloon tube. The balloon channel carries a valve that
enables blocking the balloon with fluid. The recommended
volume of blocking fluid is 1 mL, resulting in a diameter of
the balloon of 8 mm. The balloon is densely draped onto the
catheter to allow for an easy insertion through the cervical
canal. The distal end of the catheter is rounded, and its in-
sertion through the cervical canal is atraumatic. To enable
measuring the depth of the insertion, the catheter carries a
length marking.
Gynecologists received a 1-page written instruction on
the UtL procedure. The lavage can either be performed on a
gynecologic examination chair in an outpatient setting,
preferably under LA or in Lloyd-Davies position in the op-
erating theater under general anesthesia. First, the cervix is
visualized using a speculum and cleaned with an antiseptic
lotion. The cervix is graspedwith a tenaculum at 12:00 o’clock.
The catheter is inserted into the uterine cavity through the
cervical canal, and the balloon is inflated. If the cervical canal
is too narrow to pass the catheter, it is dilated to 4 mm with
Hegar’s dilators. Two 10-mL syringes, one of them containing
10 mL of phosphate-buffered saline at body temperature, are
connected to the 2 tubes of the 3-way catheter. The patient is
put into antiYTrendelenburg positioning. To initiate the la-
vage flow, 1 mL of the lavage fluid is flushed into the uterine
cavity before aspiration is started through the other lavage
channel. Subsequently, the remaining fluid is slowly
flushed and simultaneously aspirated. Particularly at the
beginning of the UtL procedure, attention should be paid
not to lose any lavage fluid. In premenopausal women, the
UtL should be performed in the late luteal phase, given the
physiologic function of the fallopian tubes. After the lavage is
finished, the balloon is deflated and the catheter is removed.After
collection, the lavage sample was mixed with an alcohol-based
stabilization solution and sent to the Medical University of
Vienna.The lavage sampleswere filtered through a 100-Kmpore
size filter. The filtrate was centrifuged at 300g for 10 minutes at
room temperature. The cell pellet was lysed and stored at
j80-C until further processing. DNA was isolated using the
QIAamp MinElute Media Kit (Qiagen, Hilden, Germany) and
quantified using a Qubit fluorometer (ThermoFisher,Waltham,
Massachusetts).
Local anesthesia was performed, following a protocol
published by Rogstad et al.10 Xylocaine spray was first ap-
plied to the cervix. After 1 minute, xylocaine 2% with
TABLE 1. Key characteristics and evaluation criteria for study I and study II
Key Characteristics Study I Study II





Catheter lots 4 1
UtL Immediately before surgery 4 wk before IUD placement
Anesthesia General Local*













- Pain during UtL
0Y10
- Pain during IUD insertion
0Y10
- Pain in the interim period
0Y10
- Side effects, complications
Description
- Time for UtL
min
- Time for IUD placement
min
*Local anesthesia was applied in 18 of 22 women before UtL and IUD insertion; in 1 woman, LAwas applied just before IUD. In 3 women,
both UtL and IUD insertion was performed without LA.
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epinephrine was injected into the ectocervix at 6 and 12
o’clock using a 20G spinal needle. The first 1 to 2 mL are
injected into the lymph vascular network of the most super-
ficial submucosal layer of the ectocervix. Only then, the
cervix is grasped with the tenaculum, and deep stromal in-
filtration to a depth of approximately 5 cm is performed, again
at 6 and 12 o’clock.
The design and the primary outcome measures of study
I are shown in Table 1. Between September 2014 and August
2015, 93 women from 4 different institutions were included:
Medical University of Vienna (Austria), Kliniken Essen-Mitte
(Germany), Charles University Pilsen (Czech Republic), and
University Medical Center Hamburg-Eppendorf (Germany).
All samples were collected in accordance with the institutional
review boards (EK nos. 1152/2014, 1148/2011, NCT02039388,
NCT02518256). Informed consent was obtained from each
participant. All patients underwent surgery, either for removal of
a suspicious ovarianmass (n = 64) or for RRSO (n= 29; Table 2).
Uterine and tubal lavage was performed before surgery under
general anesthesia. Inclusion criteria were age greater than
18 years, no pregnancy, and no prior tubal ligation. Within
this study, 16 different gynecologists performed the UtL.
Four different lots of the catheter were used.
As part of study I, the clinician performing the UtL was
asked to report on the volume of retrieved lavage fluid,
whether inserting the catheter was easy or complicated and
whether cervical dilatation was applied. The rating ‘‘com-
plicated’’ was used if access to and visualization of the cervix
was difficult, for instance, in case of vaginal stenosis or
distortion of anatomy by large benign or malignant tumors, or
if problems during dilatation were experienced, like in cases
of cervical occlusion. In the absence of any of the previously
mentioned, the rating was ‘‘easy.’’
The design of study II is shown in Table 1. This study
was carried out at the Medical University of Vienna between
October 2015 and August 2016 and included 22 healthy
women. It was conducted in accordance with the institutional
review board (EK no. 1161/2015), and informed consent was
obtained from each woman. The study involved 2 visits for
each participant. At the first visit, a UtL was performed; at the
second visit, 4 weeks later, an IUD was inserted. If needed,
UtL and/or IUD insertion was performed under LA as de-
scribed in the previous section.
Participants of study II were asked to report their sub-
jective pain on a visual analog scale (VAS) ranging from 0 (no
pain) to 10 (worst possible pain), experienced both during
UtL and IUD procedure. Participants also reported on any
possible pain, complications, or adverse effects experienced
in the 4 weeks between the 2 visits. The following parameters
TABLE 2. Characteristics of the study population
included in study I and study II and the site of
sample collection
Study I Study II
Diagnosis, n (%) 93 (100) 22 (100)
OC 33 (35.5) 0
Other cancer 6 (6.5) 0
Borderline tumor 4 (4.3) 0
HBOC 29 (31.2) 0
Benign 21 (22.6) 0
Healthy 0 22 (100)
Age, mean (range), y 51 (19Y80) 30 (21Y50)
Menopause status, n (%)
Premenopausal 40 (43.0) 22 (100)
Postmenopausal 53 (57.0) 0
Center, n (%)
Vienna 43 (46.2) 22 (100)
Essen 38 (40.9) 0
Hamburg 4 (4.3) 0
Pilsen 8 (8.6) 0








Not applied 52 (56.5%)
UtL sample collection
Successful 92 (98.9%)
Not successful 1 (1.1%)
Sample material
Sample volume 8.5 mL (range, 2.5Y10.0 mL)




Without LA (n = 4) 2.9 (2.5Y8.2)
With LA (n = 18) 1.6 (0.0Y3.9)
IUD
Without LA (n = 3) 4.0 (3.5Y6.3)
With LA (n = 19) 1.0 (0.0Y4.0)




With side effects (n = 7) 2.2 (1.0Y3.0)
Duration
UtL 6.5 min (range, 5.0Y10.0 min)
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were recorded: any use of analgesics or antibiotics, fever, and
need for medical consultation. Furthermore, the duration of
both procedures was noted.
The comparison of the catheter and lavage performance
in postmenopausal and premenopausal women, as well as
between the groups of women with different diagnoses, was
performed using the W2 test. P values were calculated using
either the 2-tailed t test or the Fisher exact test. All statistical
analyses were performed using IBM SPSS Statistics for
Windows, Version 21.0 (IBM Corp, Armonk, NY).
RESULTS
Characteristics of the study population of study I and
study II are summarized in Table 2.
In study I, 16 different gynecologists in 4 centers
performed aUtL in 93women. An overviewon the performance
data is given in Table 3. Dilation was applied in 40 women,
whereas aUtLcould be performedwithout dilation in 52women.
Overall, catheter insertion was described as easy in 78 cases and
complicated in 15 cases. The insertion was described as easy in
all 52 cases without cervical dilatation and in 65% of those cases
with cervical dilatation before UtL (Pearson W2, 2-tailed, P G
0.001). The odds ratio (OR) of difficult insertion was almost 6-
fold higher in cancer patients (n = 42) than inwomenwith benign
gynecologic diseases or those undergoing RRSO (n = 50; OR
5.559; 95% confidence interval [CI], 1.434Y21.546; Pearson W2,
2-tailed,P= 0.007). Ease of insertionwas not associatedwith the
menopause status neither in the cancer patients nor in the control
group; however, cervical dilatation before UtL was significantly
associated with postmenopausal status in the control group (OR,
4.929; 95% CI, 1.439Y16.884; Fisher exact test, 2-tailed, P =
0.016) but not in the cancer patients.
In all but 1 case (92/93; 98.9%), it was possible to collect
a UtL sample. The only exception was the case of a 68-year-old
woman with a uterine carcinoma. A tumor mass present in the
pelviswith a diameter of approximately 30 cm did not allow for
visualizing the cervix, and as a result, UtL could not be
performed. Themedianvolume of the lavage fluid, which could
be retrieved, was 8.5 mL (range, 2.5Y10.0 mL) of the 10 mL
used for performing the lavage (Table 3). DNA was isolated
from 86 of 93 UtL samples collected in the course of study I.
The median absolute amount of DNA obtained was 2.23 Kg
(range, 111 ng to 76.3 Kg; Table 3). There was no significant
difference in the amount of DNA isolated from lavage samples
depending on the patient’s diagnosis.
Because the UtL follows all steps of the insertion of an
IUD, their invasiveness is very similar. Therefore, the burden
of both procedures was compared and patients were asked to
report their subjective pain on a VAS scale immediately after
UtL and IUD insertion (Table 3). Initially, 4 patients underwent
a UtL without LA. The median VAS score reported by these
womenwas 2.9. However, one of them experienced a high level
of pain with a rating of 8.2. Because this seemed unacceptably
high for a routine procedure, in all other cases, LAwith xylocaine
spray followed by xylocaine infiltration was introduced for both
UtL and IUD insertion. Women who received LA before both
procedures rated thepain experiencedbyUtLwith amedianVAS
score of 1.6. The insertion of an IUD was rated with 1.0. In the
period between the 2 procedures, none of the 22women required
analgesic or antibiotic treatment and none of them developed a
fever or any other symptoms requiring medical attention.
Five of the participants had an IUD in place by the time
the UtL was performed. This did not cause any problems,
neither regarding performing the lavage nor regarding the
IUD position, which was checked by vaginal ultrasound af-
terwards. Seven women had a vaginal delivery previously.
The VAS score reported by these women was not significantly
different from the score of nulliparous women.
The duration of both procedures from insertion to re-
moval of the speculum was recorded for all of the 22 par-
ticipants of study II. For both of the procedures, the median
time to perform them was 6.5 minutes, ranging from 5 to 10
minutes for the UtL and 4 to 8 minutes for the IUD insertion
(Table 3 and Fig. 2).
FIGURE 2. Time to perform the UtL and IUD insertion as part of study II measured from insertion to removal of the
speculum. For both procedures, themedian timewas 6.5minutes (range, 5Y10minutes for UtL and 4Y8minutes for IUD).
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DISCUSSION
State-of-the-art diagnostic tests, namely, the assessment
of the serum CA125 level and transvaginal ultrasonography,
have already been implemented in 1988. Since then, they have
not evolved substantially, despite lacking sensitivity and
specificity.11 The molecular analysis of UtL specimens holds
great potential for earlier diagnosis of ovarian cancer (OC).
The present studies are the first to assess the clinical feasi-
bility and potential safety of the UtL approach using the newly
developed catheter.
The special configuration of the tip of the catheter made
it possible to overcome technical problems not yet solved
before. The small size allows the tip to completely enter the
uterine cavity even in postmenopausal and nulliparous
women. The catheter performed very reliably, and in 92 of
93 cases, a sample could be collected with a median volume of
8.5mL from the initial lavagevolumeof 10mL.Awritten 1-page
instruction was thus sufficient to enable gynecologists to handle
the catheter and successfully perform the procedure. Difficulties
experienced while inserting the catheter were mainly associated
with the presence of a tumor mass.
As a result of the increasing awareness, more and more
women decide to get tested for the presence of a germline
BRCAmutation. The reported rates of RRSO among mutation
carriers vary between 13% and 75%.12Y20 In a study by Skytte
et al,21 41% of women (63/155) opted for an RRSO before
their 40th birthday, although the recommended age for
performing the procedure is between 35 and 40 years. Hence,
for the remaining 59%, there is a strong unmet clinical need
for a screening test. One of the prerequisites for such a test is
being well tolerated. One of the participants of study II had a
pain rating of 8.2 while performing the UtL without anes-
thesia. This is unacceptably high for a screening test. After
introduction of LA, the median VAS scores were 1.6 for UtL
and 1.0 for IUD insertion, which is why we recommend to use
LA for all patients. For comparative reasons, median VAS
scores for peripheral intravenous cannula insertion with or
without lidocaine cream were reported to be 3.0 and 7.0,
respectively.22 Our data compare favorably with a recent study
applying conventional paracervical block for IUD insertion.23
In this study, the median VAS score after IUD insertion in
47 women was 30.0 (95% CI, 20.0Y58.0) on a 100-mm
VAS. This difference can be explained by our technique for
LA. Not only did we use a xylocaine spray first, but we also
injectedxylocaine into the ectocervixwithin a 2-stepprocedure.
First, injection into the submucosal lymph-vascular space was
performed, which results in hardly any resistance to the infil-
tration. In the second step, the deep stromal infiltration is
performed. In the period between the 2 procedures, none of the
patients required medical attention or medication, and the only
side effect seen in 7womenwas amild dragging sensation in the
lower abdomenon the day afterUtLwith amedianVASscore of
2.2 (range, 1.0Y3.0). Thus, our data clearly refute concerns
regarding the invasiveness of the UtL approach and prove that it
is well tolerated and only takes a median time of 6.5 minutes
from insertion to the removal of the speculum.
Deep sequencing should be considered the method of
choice for detecting low-level signatures of tumor-derived
mutations in liquid biopsies. The accuracy and sensitivity
of these technologies have improved tremendously over the
last years. Duplex sequencing, for example, reduced the error
rate to less than 1 in 10 million nucleotides.24 Taking that into
account, a detection limit of 0.05% is feasible, when 100 ng of
input DNA is used. All of the samples fulfilled this criterion.
In this article, we do not report on the sensitivity of OC
detection based on UtL samples because it was not the goal of
the particular studies. However, the findings of our earlier
proof-of-concept study have been very encouraging, as we
have been able to demonstrate the potentially high diagnostic
power of the UtL approach for ovarian and endometrial cancer
detection. In 24 (80%) of 30 patients with OC, specific
mutations could be identified in the UtL sample, including 1
patient with occult HGSC. Currently, the UtL approach is
studied in 3 different fields of scientific research, namely, as
a possible screening tool for HGSCs and STICs (LUSTIC,
NCT02039388), for type II endometrial carcinomas (LUDEC,
NCT02387645), and for the differential diagnosis of suspicious
adnexal masses (LUDOC II, NCT02518256). Early detection of
ovarian cancer using uterine lavage and duplex sequencing is
explored further within the frame of a National Cancer Institute
(United States) grant (www.sbir.gov/sbirsearch/detail/1323913).
In conclusion, the studies presented here demonstrate
that the UtL performed with the new catheter fulfills all
prerequisites for a screening test. Uterine and tubal lavage
specimens can be collected reliably, even after a short training.
The procedure was proven to be safe and feasible to use in a
clinical or outpatient setting. Only minimal pain was asso-
ciated with the procedure and the duration was short, which
allows for longitudinal measurements. A series of applica-
tions are conceivable and need to be proven in large, pro-
spective trials, ranging from differential diagnosis of ovarian
masses to HGSC screening in HBOC women and ultimately
screening of the general population.
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